You are here: Home » News-CM » Companies » News
Business Standard

Dr Reddy's Laboratories gets USFDA approval to launch Doxorubicin Hydrochloride Liposome Injection

Capital Market 

In United States market

Dr Reddy's Laboratories announced that it has received approval from USFDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, in the United States market.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Dr Reddy's Laboratories gets USFDA approval to launch Doxorubicin Hydrochloride Liposome Injection

In United States market

In United States market

Dr Reddy's Laboratories announced that it has received approval from USFDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, in the United States market.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Dr Reddy's Laboratories gets USFDA approval to launch Doxorubicin Hydrochloride Liposome Injection

In United States market

Dr Reddy's Laboratories announced that it has received approval from USFDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil, for intravenous use, in the United States market.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22